Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi Eyes EUA of COVID Pill in South Korea via Sublicense to Local Firm
September 20, 2022
- Asahi Kasei Bags Japan Commercial Rights for Two Sobi Treatments
September 16, 2022
- Kyowa Kirin Seeks Palmoplantar Pustulosis Nod for Lumicef in Japan
September 16, 2022
- Insmed CEO Sees Japan as Cornerstone of APAC Strategy, Doubling of Staff in Next 2 Years
September 16, 2022
- Novartis’s Sandimmun Faces Post-Recall Stockout, Re-Supply Expected after Late October
September 15, 2022
- Moderna to Have One of Industry’s Biggest Pipelines in 5 Years, Oncology Might Make Up 30% of Sales: CEO
September 15, 2022
- Eisai on Course towards 500-Billion-Yen Mark in Global Lenvima Sales as Trials Progress: Eisai Official
September 14, 2022
- Lonsurf-Bevacizumab Combo Extends Survival in PIII Colorectal Cancer Trial
September 14, 2022
- Otsuka/Lundbeck’s 2-Month Aripiprazole Injectable Accepted for FDA Review
September 14, 2022
- Alnylam Japan Paints Two-Digit Annual Growth Outlook on ATTR Meds and Pipeline Drugs
September 14, 2022
- Lenvima-Keytruda for HCC Misses PIII Primary Goal: Eisai/Merck
September 13, 2022
- Otsuka’s Brexpiprazole Yields Positive Japan PIII Results for Major Depression
September 13, 2022
- Pfizer Seeks Japan Nod for BA.4/5-Adapted COVID-19 Vaccine
September 13, 2022
- Santen CEO Taniuchi Bows Out for Personal Reasons, EVP Ito Takes Helm
September 13, 2022
- Cosentyx 300 mg Pen Approved in Japan: Novartis
September 13, 2022
- Daiichi’s ADC DS-7300 Shows 32% Response in PI/II Solid Tumor Trial
September 13, 2022
- Enhertu Shows Clinically Meaningful Activity in HER2 Mutant NSCLC: Daiichi/AZ
September 13, 2022
- Moderna CEO Visits Fukuoka for Potential Collaboration with Japan
September 13, 2022
- Kowa Files Parmodia Extended-Release Version in Japan
September 13, 2022
- Japan’s First CAD Therapy, Enjaymo, Now Available: Sanofi
September 9, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…